1p19q Deletion by FISH and IDH1 R132H Point Mutation by Immunohistochemistry with Reflex to IDH1 and IDH2 Mutation Analysis, Exon 4 - Clinical Genetic Test - GTR

1p19q Deletion by FISH and IDH1 R132H Point Mutation by … see more 1p19q Deletion by FISH and IDH1 R132H Point Mutation by Immunohistochemistry with Reflex to IDH1 and IDH2 Mutation Analysis, Exon 4 see less

Clinical Genetic Test

offered by

ARUP Laboratories, Molecular Oncology

View lab's test page

GTR Test Accession: GTR000591526.1

NYS CLEP

CANCERNERVOUS SYSTEM

Last updated in GTR: 2020-08-24

Last annual review date for the lab: 2023-11-27

At a Glance

Test purpose:

Prognostic; Diagnosis; Therapeutic management

Conditions (2):

Glioma; Oligodendroglioma

Analytes (1):

1p and 19q deletion, IDH1 R132H mutation by IHC

Genes (1):

IDH1 (2q34)

Methods (2):

Biochemical Genetics - Immunohistochemistry: Immunohistochemistry; ...

Target population:

Not provided

Clinical validity:

Not provided

Clinical utility:

Not provided

Ordering Information

Offered by:

ARUP Laboratories, Molecular Oncology
View lab's website
View lab's test page

Who can order:

Health Care Provider

Test Order Code:

3002135

Contact Policy:

Laboratory can only accept contact from health care providers. Patients/families are encouraged to discuss genetic testing options with their health care provider.

Informed consent required:

Decline to answer

Pre-test genetic counseling required:

Decline to answer

Post-test genetic counseling required:

Decline to answer

Recommended fields not provided:

How to Order, Specimen source, Lab contact for this test, Test strategy, Test development

Conditions

Total conditions: 2

Condition/Phenotype	Identifier

Test Targets

Analytes

Total analytes: 1

Analyte	Associated Condition

Genes

Total genes: 1

Gene	Associated Condition	Germline or Somatic	Allele (Lab-provided)	Variant in NCBI

Methodology

Total methods: 2

Method Category

Test method

Instrument *

Immunohistochemistry

Sequence analysis of select exons

Bi-directional Sanger Sequence Analysis

* Instrument: Not provided

Clinical Information

Test purpose:

Prognostic; Diagnosis; Therapeutic management

Recommended fields not provided:

Clinical validity, Clinical utility, Target population, What is the protocol for interpreting a variation as a VUS?, Is research allowed on the sample after clinical testing is complete?, Sample negative report, Sample positive report

Technical Information

Availability:

Tests performed
Entire test performed in-house

Analytical Validity:

For IDH1 and IDH2 sequencing, the limit of detection is 20 percent mutant allele.

Proficiency testing (PT):

Is proficiency testing performed for this test?
No

Recommended fields not provided:

Test Confirmation, Assay limitations, Description of internal test validation method, Citations for Analytical validity, PT Provider, Description of PT method, Major CAP category, CAP category, CAP test list

Regulatory Approval

FDA Review:

Not provided

NYS CLEP Approval:

Number:
Status: Approved

Additional Information

Reviews:

PubMed Clinical Queries

Clinical resources:

Practice guidelines:

Consumer resources:

NCATS Office of Rare Diseases Research (GARD)

MedlinePlus

IMPORTANT NOTE: NIH does not independently verify information submitted to GTR; it relies on submitters to provide information that is accurate and not misleading. NIH makes no endorsements of tests or laboratories listed in GTR. GTR is not a substitute for medical advice. Patients and consumers with specific questions about a genetic test should contact a health care provider or a genetics professional.